|
|
|
| Effect of L-carnitine Combined with Furosemide on Heart Failure Treatment in Patients with Chronic Kidney Disease undergoing Hemodiafiltration |
| JIANG Jia-wei |
| Department of Nephrology, Yixing people's Hospital, Jiangsu Yixing 214200 |
|
|
|
|
Abstract 【Objective】To investigate the efficacy of L-carnitine combined with furosemide in the treatment of heart failure patients with chronic kidney disease(CKD)undergoing hemodiafiltration (HDF). 【Methods】A total of 120 CKD patients with HDF, who complicated with heart failure, were randomly divided into two groups. The control group received proper HDF and conventional anti-heart failure treatment. While the observation group received intravenous injection of L-carnitine and furosemide on the basis of treatment in the control group. Patients in the two groups were treated continuously for 12 weeks . Cardiac function indicators, angiotensin (Ang Ⅱ), plasma renin (PRA), aldosterone (ALD) and N-terminal pro-brain natriuretic peptide (NT-proBNP), 6 min walking distance(6MWT) and incidence of adverse reactions were compared between two groups. 【Results】After treatment, the total effective rate of the observation group was 91.67% (55/60), which was significantly higher than that of the control group 75.00% (45/60); the difference was statistically significant (P<0.05). In both groups, the levels of AngⅡ, PRA, ALD, NT-proBNP, cardiac index (CI), LVEDD, LVPWT and IVST after treatment were significantly lower than those before treatment; While the levels of LVEF and 6MWT were significantly higher than those before treatment (P<0.05). The improvement level of the observation group was more obvious than that of the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). 【Conclusion】The application of L-carnitine combined with furosemide in the treatment of heart failure patients with CKD undergoing HDF has good efficacy, which shows significant improvement of patients' cardiac function and 6MWT. It is safe and worthy of clinical application.
|
|
Received: 06 September 2018
|
|
|
|
|
|
[1] Zumbrennen-Bullough K. The iron cycle in chronic kidney disease (CKD): from genetics and experimental models to CKD patients[J].Nephrol Dial Transplant,2014,29(2):263-273.
[2] 郭皓. 厄贝沙坦联合左卡尼汀治疗维持性血液透析滤过患者心力衰竭的疗效观察[J].中国现代医生. 2014. (07): 70-72.
[3] 王斯闻, 陈达, 田焕, 等. 左卡尼汀对老年冠心病慢性心力衰竭心功能的影响[J].医学临床研究, 2012,(2):195-197.
[4] 贾英民, 霍延红, 杨永红, 等. 左卡尼汀治疗终末期肾病维持性血液透析滤过患者心功能不全的临床效果[J].中国医药, 2015,(10):1499-1501.
[5] 唐瑞康. 左卡尼汀治疗心血管疾病的临床应用[J].当代医学, 2012,(18):22-24.
[6] Yancy CW, Jessup M, Bozkurt B,et al.2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines[J].J Am Coll Cardiol,2013,62(16):e147-239.
[7] 王垒, 刘慧, 李允, 等. 托拉塞米联合左卡尼汀治疗慢性心力衰竭急性加重期的临床研究[J].现代药物与临床, 2018,(01):79-83.
[8] 高子任. 银杏总黄酮对心衰大鼠心功能及AngⅡ、ET-1的影响[J].中华中医药杂志, 2014,(11):3547-3549.
[9] Ahn YH, Lee KS, Park JH,et al.Independent risk factors for mortality in patients with chronic obstructive pulmonary disease who undergo comprehensive cardiac evaluations[J].Res,2015,90(3):199-205. |
| [1] |
. [J]. JOURNAL OF CLINICAL RESEARCH, 2019, 36(9): 1820-1821. |
|
|
|
|
2019, Vol. 36 
